Press coverage about Becton Dickinson and (NYSE:BDX) has been trending somewhat positive recently, according to AlphaOne. The research firm, a unit of Accern, identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Becton Dickinson and earned a news sentiment score of 0.02 on AlphaOne’s scale. AlphaOne also gave media stories about the medical instruments supplier an impact score of 36 out of 100, meaning that recent media coverage is unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Alpha One Sentiment’s analysis:
- Becton, Dickinson & Co. – Value Analysis (NYSE:BDX) : April 19, 2017 (finance.yahoo.com)
- Global Catheter Market 2017 – Abbott Laboratories, Becton Dickinson Inc., Boston Scientific, Arrow International Inc (medgadget.com)
- North American Management Corp Sells 107 Shares of Becton Dickinson and Co (BDX) (automotive.einnews.com)
- A Quick Look at Becton Dickinson and Company (BDX) – Nelson Research (nlrnews.com)
- Becton Dickinson and (BDX) Receives Coverage Optimism Rating of 0.10 (americanbankingnews.com)
A number of equities analysts recently commented on the company. Royal Bank of Canada restated a “hold” rating and set a $177.00 target price on shares of Becton Dickinson and in a report on Thursday, April 13th. JPMorgan Chase & Co. downgraded Becton Dickinson and from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $190.00 to $175.00 in a report on Tuesday, January 3rd. Jefferies Group LLC restated a “buy” rating and set a $200.00 target price on shares of Becton Dickinson and in a report on Wednesday, March 29th. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 target price for the company in a report on Tuesday, April 11th. Finally, Raymond James Financial, Inc. reiterated an “outperform” rating and issued a $180.00 price objective (down previously from $200.00) on shares of Becton Dickinson and in a report on Thursday, January 5th. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $182.91.
Becton Dickinson and (NYSE:BDX) traded down 0.64% during midday trading on Friday, hitting $184.86. The company had a trading volume of 130,802 shares. The stock has a market capitalization of $39.34 billion, a PE ratio of 30.77 and a beta of 1.00. The stock has a 50 day moving average price of $183.77 and a 200-day moving average price of $175.25. Becton Dickinson and has a 52 week low of $157.60 and a 52 week high of $186.40.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.22. The firm had revenue of $2.92 billion for the quarter, compared to analysts’ expectations of $2.86 billion. Becton Dickinson and had a return on equity of 25.25% and a net margin of 10.54%. The firm’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.96 EPS. On average, equities analysts predict that Becton Dickinson and will post $9.45 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, March 31st. Investors of record on Friday, March 10th were given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.57%. The ex-dividend date of this dividend was Wednesday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 48.42%.
In related news, VP Jeffrey S. Sherman sold 31,464 shares of the business’s stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $180.02, for a total value of $5,664,149.28. Following the transaction, the vice president now owns 22,094 shares in the company, valued at approximately $3,977,361.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/04/21/becton-dickinson-and-bdx-earns-news-sentiment-rating-of-0-02-updated.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co and related companies with MarketBeat.com's FREE daily email newsletter.